ContactISSN:e-ISSN: 2757-976X
Author Sign-inReviewer Sign-inRegister
TürkçeEnglish
Home
About Journal
Copyright NoticeOpen Access PolicyAim and ScopePrinciples of ArbitrationReviewer and Editor GuideFee PolicyEthical Principles and Publication PolicyArchiving PolicyIndexing
Information For AuthorsEditorial BoardSend ArticleLatest IssueArchiveContact Us

EFFECTS OF CHEMOTHERAPEUTİC AGENTS ON SERUM ELECTROLYTE LEVELS IN HEMATOLOGICAL MALIGNANCIES

Elif Kerimoğlu,MEHMET ASİL,ÖZCAN ÇENELİ

  • Elif Kerimoğlu: ORDU EĞİTİM ARAŞTIRMA HASTANESİ
  • MEHMET ASİL: KONYA NECMETTİN ERBAKAN ÜNİVERSİTESİ
  • ÖZCAN ÇENELİ: NEÜ MERAM TIP FAKÜLTESİ
  •  Year : 2024
  •  Vol : 4
  •  Issue : 1
  •  Page : 1-6
Aim: This study aimed to investigate the changes in serum levels of various electrolytes on the 1st day of treatment in patients receiving chemotherapy due to hematological malignancies.
Patients and Methods: Serum levels of various electrolytes before and after the first course of chemotherapy were compared retrospectively in patients receiving chemotherapy for hematological malignancies between 2010-2014.
Results: Data from 195 patients were analyzed. Serum calcium concentrations decreased significantly in multiple myeloma (p=0.013), Hodgkin lymphoma (p=0.03) and non-Hodgkin lymphoma (p=0.002) groups after chemotherapy compared to pre-chemotherapy levels. In the chronic lymphocytic lymphoma group sodium (p=0.017) and magnesium (p=0.006) concentrations, in the acute myeloid leukemia group sodium concentration (p=0.012) were decreased significantly after chemotherapy. In the acute lymphoblastic leukemia group, magnesium concentration significantly increased after chemotherapy (p=0.028).
Conclusion: In patients receiving chemotherapy for hematological malignancies significant changes occur in plasma concentrations of serum electrolytes even in the early period after chemotherapy.
Cite this Article As : Kerimoğlu E, Asıl M, Çeneli Ö. Hematolojik Malignitelerde Kemoterapi Ajanlarının Serum Elektrolit Düzeylerine Etkisi. Mev Med Sci. 2024; 4(1): 1-6

Conflict of interest : The authors declare that they have no conflict of interest.

This article is published under the CC BY-NC 4.0 license.
Mevlana Tıp Bilimleri
2024, Vol4, Issue1
E-ISSN: 2757-976X
Received : , Accepted : , Published Online :

References

  1. 1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7-30. doi: 10.3322/caac.21387.
  2. 2. Tekinalp A, Çeneli Ö, Güzel ME, ve ark. SARS-CoV-2’nin Hematolojik Hastalıklar Üzerindeki Etyolojik Rolü. Selcuk Med J 2022;38(1): 40-44. doi: 10.30733/std.2022.01538
  3. 3. Morris EC, Neelapu SS, Giavridis T, et al. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22(2):85-96. doi: 10.1038/s41577-021-00547-6.
  4. 4. Bose P, Simmons GL, Grant S. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opin Investig Drugs. 2013;22(6):723-38. doi: 10.1517/13543784.2013.789859.
  5. 5. Dahlgren D, Sjöblom M, Hellström PM, et al. Chemotherapeutics-Induced Intestinal Mucositis: Pathophysiology and Potential Treatment Strategies. Front Pharmacol. 2021;12:681417. doi: 10.3389/fphar.2021.681417.
  6. 6. Tekinalp A, Demircioğlu S, Bilgen H ve ark. B12 Vitamini Düzeyinin Multiple Miyelom Kliniğine Etkisi. Selcuk Med J 2021;37(1): 11-16. doi: 10.30733/std.2020.01472.
  7. 7. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127(1):3-11. doi: 10.1111/j.1365-2141.2004.05094.x.
  8. 8. Lupușoru G, Ailincăi I, Frățilă G, et al. Tumor Lysis Syndrome: An Endless Challenge in Onco-Nephrology. Biomedicines. 2022;10(5):1012. doi: 10.3390/biomedicines10051012.
  9. 9. Chen Z, Peng H, Zhang C. Advances in kidney-targeted drug delivery systems. Int J Pharm. 2020;587:119679. doi: 10.1016/j.ijpharm.2020.119679.
  10. 10. Tang TT, Lv LL, Wang B, et al. Employing Macrophage-Derived Microvesicle for Kidney-Targeted Delivery of Dexamethasone: An Efficient Therapeutic Strategy against Renal Inflammation and Fibrosis. Theranostics. 2019;9(16):4740-4755. doi: 10.7150/thno.33520.
  11. 11. Ciftciler R, Haznedaroglu IC, Aksu S, et al. The Factors Affecting Early Death in Newly Diagnosed APL Patients. Open Med (Wars). 2019;14:647-652. doi: 10.1515/med-2019-0074.
  12. 12. Sørensen JB, Andersen MK, Hansen HH. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J Intern Med. 1995;238(2):97-110. doi: 10.1111/j.1365-2796.1995.tb00907.x.
  13. 13. Morikawa G, Kinjo T, Hanaoka Y, et al. [Life-Threatening Hyponatremia by Chemotherapy in a Patient with Non-Hodgkin's Lymphoma]. Gan To Kagaku Ryoho. 2015;42(13):2493-6. Japanese.
  14. 14. Marcus R, Hagenbeek A. The therapeutic use of rituximab in non-Hodgkin's lymphoma. Eur J Haematol Suppl. 2007;(67):5-14. doi: 10.1111/j.1600-0609.2006.00789.x.
  15. 15. Daniels I, Turzanski J, Haynes AP. A requirement for calcium in the caspase-independent killing of Burkitt lymphoma cell lines by Rituximab. Br J Haematol. 2008;142(3):394-403. doi: 10.1111/j.1365-2141.2008.07193.x.